

BETTER PRODUCTS

BryoTechnology offers a wide range of advantages for biopharmaceutical development and production processes. Our broad IP portfolio covers plant production processes, N-glycosylation techniques, proprietary drug candidates, and mechanisms-of-action. We offer contract manufacturing and licensing models.

CONTACT

Manon Kirstein
Head of Business Development
Phone + 49 761 470 99 0
bd@greenovation.com
www.greenovation.com


**DIFFICULT-TO-EXPRESS
PROTEINS
SUCCESSFULLY
PRODUCED IN MOSS**

GREENOVATION

Biopharmaceuticals

BRYOTECHNOLOGY FOR YOUR DIFFICULT-TO-EXPRESS, COMPLEX, GLYCO-ENGINEERED, POSTTRANSLATIONALLY MODIFIED, MULTIMERIC, OR TOXIC PROTEIN

ALL SUCCESSFULLY EXPRESSED WITH BRYOTECHNOLOGY



Full range of contract development and manufacturing

Greenovation offers the full range of contract development and manufacturing from small-scale feasibility studies to validated clinical- and commercial-scale production processes. This enables our clients not only to test potential protein candidates quickly, but also to receive drug substance for clinical trials and the market.

OUR SERVICES

- Cell line development
- Cell banks
- Process development and upscaling, upstream and downstream
- Contract manufacturing
- PoC studies

Outstanding product quality

Exploiting the unique advantages of the moss *Physcomitrella patens*, BryoTechnology is a production process based on single-use technology and mineral fermentation media free of antibiotics and animal-derived components. The process is cGMP-compliant, highly scalable and allows for straightforward tech transfer to any given manufacturing plant.

YOUR ADVANTAGES

- Glyco-designed products
- High levels of batch-to-batch homogeneity
- Customized production strains
- Free of animal components
- Antibiotic-free